ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 89 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,488 | +32.3% | 31,309 | +18.8% | 0.00% | – |
| Q2 2023 | $270,868 | -27.2% | 26,349 | -45.3% | 0.00% | – |
| Q1 2023 | $372,000 | +354185.7% | 48,149 | +238.4% | 0.00% | – |
| Q4 2022 | $105 | -99.9% | 14,230 | +34.6% | 0.00% | – |
| Q3 2022 | $77,000 | -6.1% | 10,573 | +9.3% | 0.00% | – |
| Q2 2022 | $82,000 | +2.5% | 9,669 | +8.1% | 0.00% | – |
| Q1 2022 | $80,000 | -20.8% | 8,947 | +23.4% | 0.00% | – |
| Q4 2021 | $101,000 | +110.4% | 7,250 | +62.6% | 0.00% | – |
| Q3 2021 | $48,000 | +20.0% | 4,460 | 0.0% | 0.00% | – |
| Q2 2021 | $40,000 | -45.2% | 4,460 | -23.5% | 0.00% | – |
| Q4 2020 | $73,000 | – | 5,830 | +194233.3% | 0.00% | – |
| Q3 2020 | $0 | – | 3 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 3 | -99.9% | 0.00% | – |
| Q3 2017 | $30,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |